LQ036

Phase 2Small molecule

SSyneos Health

LQ036 is one of 27 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaRecruiting

AsthmaPhase 2

Recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

LQ036

SSyneos Health

Phase 2

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Asthma

NCT07589439

Clinical

Trials by Indication[1]

Immunogenicity1 trial

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Terminated·SSyneos Health·Phase 1·NCT04993443·40 enrolled

Asthma1 trial

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of LQ036 Single-Domain Antibody Nebulization Solution in Patients With Poorly Controlled Asthma

Recruiting·SShanghai Novamab Biopharmaceuticals Co., Ltd.·Phase 2·NCT07589439·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LQ036. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LQ036 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LQ036. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syneos Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSyneos Health

LQ036

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Immunogenicity1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News